申请人:Repros Therapeutics Inc.
公开号:EP3351527A1
公开(公告)日:2018-07-25
The present invention relates to substantially pure metabolites of irara-clomiphene. The invention is also directed to pharmaceutical compositions comprising these metabolites and their use in treating disorders including secondary hypogonadism, type 2 diabetes, elevated cholesterol, elevated triglycerides, wasting, lipodystrophy, female and male infertility, benign prostate hypertrophy, prostate cancer, breast cancer, ovarian cancer and endometrial cancer.
本发明涉及伊拉拉-克罗米酚的纯代谢物。本发明还涉及由这些代谢物组成的药物组合物,以及它们在治疗继发性性腺功能减退症、2 型糖尿病、胆固醇升高、甘油三酯升高、消瘦、脂肪营养不良、女性和男性不育症、良性前列腺肥大、前列腺癌、乳腺癌、卵巢癌和子宫内膜癌等疾病中的用途。